Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.59 |
| ▸ | NPC1 | O15118 | 7/20 | 0.59 |
| ▸ | PKM | P14618 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL11274227 | 0.91 | RAB9A (0.55) | RAB9ANPC1PKMGAASMN1; SMN2 | |
| Nitric Acid SCHEMBL30925715 | 0.88 | NPC1 (0.51) | RAB9ANPC1PKMGAASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL18453970 | 0.85 | KDM4E (0.55) | RAB9ANPC1PKMGAASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL29544086 | 0.85 | KDM4E (0.55) | RAB9ANPC1PKMGAASMN1; SMN2 | |
| SCHEMBL29114633 | 0.85 | RAB9A (0.52) | RAB9ANPC1PKMGAASMN1; SMN2 | |
| SCHEMBL27548451 | 0.79 | RAB9A (0.71) | RAB9ANPC1PKMSMN1; SMN2KDM4E | |
| SCHEMBL7091557 | 0.79 | RAB9A (0.59) | RAB9ANPC1PKMGAASMN1; SMN2 | |
| SCHEMBL4021933 | 0.79 | NPC1 (0.59) | RAB9ANPC1PKMGAASMN1; SMN2 | |
| SCHEMBL10793724 | 0.79 | RAB9A (0.59) | RAB9ANPC1PKMGAASMN1; SMN2 | |
| SCHEMBL525427 | 0.79 | RAB9A (0.61) | RAB9ANPC1PKMGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014024193-A1 | COMPOSITIONS AND METHODS FOR RAPID TRANSMUCOSAL DELIVERY OF PHARMACEUTICAL INGREDIENTS | PRODEL PHARMA LTD. (IL) | 2014-02-13 | — | — | WO | claimed |
| US-20100086495-A1 | COMPOSITIONS AND METHODS FOR ENHANCING TRANSMUCOSAL DELIVERY | DERMA-YOUNG LTD. (IL) | 2010-04-08 | — | — | US | claimed |
| EP-2114384-A2 | COMPOSITIONS AND METHODS FOR ENHANCING TRANSMUCOSAL DELIVERY | Derma-Young Ltd. (IL) | 2009-11-11 | — | — | EP | claimed |
| WO-2008099397-A2 | COMPOSITIONS AND METHODS FOR ENHANCING TRANSMUCOSAL DELIVERY | DERMA-YOUNG LTD. (IL) | 2008-08-21 | — | — | WO | claimed |
| US-7087240-B1 | Device and method for the treatment of erectile dysfunction | LAVIPHARM LABORATORIES INC. (US) | 2006-08-08 | — | — | US | claimed |
| EP-1089679-B1 | A DEVICE AND METHOD FOR THE TREATMENT OF ERECTILE DYSFUNCTION | LAVIPHARM LAB INC (US) | 2005-09-07 | — | — | EP | claimed |
| EP-1089679-A1 | A DEVICE AND METHOD FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Lavipharm Laboratories, Inc. (US) | 2001-04-11 | — | — | EP | claimed |
| WO-1999066870-A1 | A DEVICE AND METHOD FOR THE TREATMENT OF ERECTILE DYSFUNCTION | LAVIPHARM LABORATORIES, INC. (US) | 1999-12-29 | — | — | WO | claimed |
| CN-114502555-B | Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridin-3-yl) pyrimidin-2-amine for the treatment of proliferative diseases and disorders | 常州千红生化制药股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-114269742-B | Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridinyl) pyrimidin-2-amine as therapeutic agents | 常州千红生化制药股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118307517-A | Preparation method of arbeli and intermediate thereof | 北京海美源医药科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240158391-A1 | DERIVATIVES OF 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-N-(PYRIDIN-3-YL) PYRIMIDIN-2- AMINE FOR TREATING PROLIFERATIVE DISEASES AND CONDITIONS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-05-16 | — | — | US | disclosed |
| CN-116640238-B | Guanidyl pyridine chitosan onium salt and preparation method and application thereof | 华侨大学 | 2024-05-03 | — | — | CN | disclosed |
| CN-116640238-B | Guanidyl pyridine chitosan onium salt and preparation method and application thereof | 华侨大学 | 2024-05-03 | — | — | CN | disclosed |
| EP-0116628-A4 | 1-ACYL-3-PYRIDYLMETHYLGUANIDINES AND THEIR USE AS ANTIHYPERTENSIVE AGENTS. | RORER INTERNAT OVERSEAS INC (US) | 1985-02-18 | — | — | EP | disclosed |
| US-4496573-A | 1-Pyridylmethyl-3-acyl guanidines | WILLIAM H. RORER, INC. (US) | 1985-01-29 | — | — | US | disclosed |
| EP-0116628-A1 | 1-ACYL-3-PYRIDYLMETHYLGUANIDINES AND THEIR USE AS ANTIHYPERTENSIVE AGENTS. | RORER INT OVERSEAS (US) | 1984-08-29 | — | — | EP | disclosed |
| WO-1984000963-A1 | 1-ACYL-3-PYRIDYLGUANIDINES AND THEIR USE AS ANTIHYPERTENSIVE AGENTS | RORER INT OVERSEAS (US) | 1984-03-15 | — | — | WO | disclosed |
| US-RE31244-E | Antihypertensive pyridylguanidine compounds | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 1983-05-17 | — | — | US | disclosed |
| US-4057636-A | Antihypertensive pyridylguanidine compounds | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 1977-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158391-A1 | DERIVATIVES OF 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-N-(PYRIDIN-3-YL) PYRIMIDIN-2- AMINE FOR TREATING PROLIFERATIVE DISEASES AND CONDITIONS | CDK9, CDK4, CDK2 | RAB9A 1762/4885NPC1 4571/4885PKM 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.